Abi Siva, Associate Professor and Director of Medical Oncology at MUSC Health Hematology Oncology at Hollings Cancer Center, shared a post on X:
“Excited to discuss one of the big questions in Breast Cancer with my good friend Carey Anders: What’s next for residual disease after DESTINY-Breast11 clinical trial?
You can also read:
DESTINY-Breast09 Shows Strong 24-Month PFS Benefit With Deep Responses
